New hope for myelofibrosis patients: tasquinimod trial launches
NCT ID NCT06327100
First seen Feb 10, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This early-stage trial is testing a drug called tasquinimod, either alone or with the standard drug ruxolitinib, in 33 people with myelofibrosis (a type of bone marrow cancer). The goal is to see if the combination is safe and can help control the disease, especially in patients who have not responded to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tasquinimod (given alone or with ruxolitinib)
What this could lead to
If it works, this could offer a new treatment option for people with myelofibrosis who have not responded to or cannot take standard therapies.
What could go wrong
This is an early-phase trial with only 33 participants, so results may not apply widely. The drug may cause side effects or fail to control the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.